remaining questions regarding the use of adjuvant chemotherapy in breast cancer
Published 1 year ago • 80 plays • Length 1:15Download video MP4
Download video MP3
Similar videos
-
1:38
unanswered questions in the use of adjuvant therapy in early breast cancer
-
8:10
mindact: adjuvant chemotherapy in breast cancer
-
1:12
remaining questions on the use of frontline cdk4/6 inhibitors endocrine therapy
-
1:03
remaining questions on the use of neoadjuvant pembrolizumab in early tnbc following keynote-522
-
2:46
adjuvant chemotherapy for breast cancer: who needs it?
-
0:56
remaining questions on the management of her2-low breast cancer
-
2:49
procure: genomic signatures and adjuvant chemotherapy for breast cancer in europe
-
1:40
unanswered questions in breast cancer
-
1:19
optimizing adjuvant therapy: chemotherapy necessity in hr-positive breast cancer
-
2:07
remaining questions regarding the use of frontline cdk4/6 inhibitors and endocrine therapy
-
2:12
the impact of adjuvant chemo on os in hr and node bc with an oncotype dx score of 25 or less
-
30:56
adjuvant treatment for early stage hormone positive breast cancer: role of genomic signatures
-
1:51
reflecting on the use of cdk4/6 inhibitors in hr breast cancer
-
6:09
adjuvant endocrine therapy for breast cancer: optimal durations and regimens
-
1:49
early breast cancer: do we need chemotherapy in low genomic/high clinical risk (er /her2-)?
-
2:20
escalation of adjuvant therapy in hr breast cancer
-
0:53
eleanor: real-world study of extended adjuvant neratinib in her2 /hr early breast cancer
-
4:27
risk model to predict delivery of adjuvant chemotherapy
-
11:07
adjuvant therapy for early stage er-positive, her2-negative invasive breast cancer